Clinical Trial Update: Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing hepatic safety of raltegravir versus efavirenz in HIV patients coinfected with hepatitis C; results completed and posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• EFAVIRENZ (efavirenz)
• Raltegravir (raltegravir)

Snippet

Sponsor: University of Hawaii | Conditions: Hepatitis C, Chronic, HIV Infection | Phase 4 | Status: COMPLETED | Results posted: 2021-08-13